Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Robotic surgery for rectal cancer: may it improve also survival?

  • 142 Accesses

  • 64 Citations

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Enker WE, Thaler HT, Cranor ML, Polyak T (1995) Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 181:335–346

  2. 2.

    Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98–107

  3. 3.

    Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9(3):220–221

  4. 4.

    Clarke M, Collins R, Darby S et al (2005) Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 366(9503):2087–2106

  5. 5.

    Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6(3):308–312

  6. 6.

    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197–198 (author reply 198)

  7. 7.

    Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8(1):29–30

  8. 8.

    Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578–590

  9. 9.

    Baik SH, Lee WJ, Rha KH et al (2007) Robotic total mesorectal excision for rectal cancer using four robotic arms. Surg Endosc (Epub ahead of print)

  10. 10.

    Roukos DH, Fatouros M, Tsianos E, Kappas AM (2006) Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification? Nat Clin Pract Oncol 3(12):656–657

  11. 11.

    Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919–932

  12. 12.

    Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607–609

  13. 13.

    Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943

  14. 14.

    Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245(6):873–879

  15. 15.

    Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(15):1555–1556 (author reply 1556)

  16. 16.

    Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15(1):21–33

  17. 17.

    Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030–1034

  18. 18.

    Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10(7):718–721

  19. 19.

    Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745

  20. 20.

    Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125

  21. 21.

    Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11(2):127–129

  22. 22.

    Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14(10):2691–2695

  23. 23.

    Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM (2001) Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 84(12):1602–1609

  24. 24.

    Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11(8):727–730

  25. 25.

    Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81(2):59–62

  26. 26.

    Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80(1):16–24

  27. 27.

    Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7(4):253–255

  28. 28.

    Briasoulis E, Liakakos T, Dova L et al (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6(6):931–939

  29. 29.

    Roukos DH (1999) Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 6:46–56

  30. 30.

    Liakakos T, Roukos DH (2008) More controversy than everchallenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol (Epub ahead of print). doi: 10.1245/s10434-007-9798-5

  31. 31.

    Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141

Download references

Author information

Correspondence to Dimosthenis Ziogas.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ziogas, D., Roukos, D. Robotic surgery for rectal cancer: may it improve also survival?. Surg Endosc 22, 1405–1406 (2008). https://doi.org/10.1007/s00464-008-9796-0

Download citation

Keywords

  • Rectal Cancer
  • Total Mesorectal Excision
  • Lynch Syndrome
  • Diffuse Gastric Cancer
  • Hereditary Diffuse Gastric Cancer